Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Spotlight on Clinical Response

  • Spotlight on Clinical Response
    Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
    David Hong, Lei Ye, Robert Gagel, Lakshmi Chintala, Adel K. El Naggar, John Wright and Razelle Kurzrock
    Mol Cancer Ther May 1 2008 7 (5) 1001-1006; DOI:10.1158/1535-7163.MCT-07-2422

Review

  • Review
    Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
    Hong Su, Lucia Altucci and Qidong You
    Mol Cancer Ther May 1 2008 7 (5) 1007-1012; DOI:10.1158/1535-7163.MCT-07-2289

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
    Lawrence P. Petalidis, Anastasis Oulas, Magnus Backlund, Matthew T. Wayland, Lu Liu, Karen Plant, Lisa Happerfield, Tom C. Freeman, Panayiota Poirazi and V. Peter Collins
    Mol Cancer Ther May 1 2008 7 (5) 1013-1024; DOI:10.1158/1535-7163.MCT-07-0177

  • Research Articles: Therapeutics, Targets, and Development
    An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector
    Guozheng Liu, Shuping Dou, Mary Rusckowski and Donald J. Hnatowich
    Mol Cancer Ther May 1 2008 7 (5) 1025-1032; DOI:10.1158/1535-7163.MCT-07-2203

  • Research Articles: Therapeutics, Targets, and Development
    Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia
    Athanasia Katsoulas, Zakaria Rachid, James P. McNamee, Christopher Williams and Bertrand J. Jean-Claude
    Mol Cancer Ther May 1 2008 7 (5) 1033-1043; DOI:10.1158/1535-7163.MCT-07-0179

  • Research Articles: Therapeutics, Targets, and Development
    Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein
    Hui Wang, Kai Chen, Weibo Cai, Zibo Li, Lina He, Amir Kashefi and Xiaoyuan Chen
    Mol Cancer Ther May 1 2008 7 (5) 1044-1053; DOI:10.1158/1535-7163.MCT-07-2084

  • Research Articles: Therapeutics, Targets, and Development
    KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
    Christian A. Hassig, Kent T. Symons, Xin Guo, Phan-Manh Nguyen, Tami Annable, Paul L. Wash, Joseph E. Payne, David A. Jenkins, Céline Bonnefous, Carol Trotter, Yan Wang, John V. Anzola, Elena L. Milkova, Timothy Z. Hoffman, Sara J. Dozier, Brandon M. Wiley, Alan Saven, James W. Malecha, Robert L. Davis, Jerry Muhammad, Andrew K. Shiau, Stewart A. Noble, Tadimeti S. Rao, Nicholas D. Smith and Jeffrey H. Hager
    Mol Cancer Ther May 1 2008 7 (5) 1054-1065; DOI:10.1158/1535-7163.MCT-07-2347

  • Research Articles: Therapeutics, Targets, and Development
    Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
    Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear and Ricky W. Johnstone
    Mol Cancer Ther May 1 2008 7 (5) 1066-1079; DOI:10.1158/1535-7163.MCT-07-2256

  • Research Articles: Therapeutics, Targets, and Development
    Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor
    Adriana S. Beltran, Xueguang Sun, Paul M. Lizardi and Pilar Blancafort
    Mol Cancer Ther May 1 2008 7 (5) 1080-1090; DOI:10.1158/1535-7163.MCT-07-0526

  • Research Articles: Therapeutics, Targets, and Development
    Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
    Karthikeyan Kandasamy and Andrew S. Kraft
    Mol Cancer Ther May 1 2008 7 (5) 1091-1100; DOI:10.1158/1535-7163.MCT-07-2368

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells
    Ningxi Zhu, Lubing Gu, Fengzhi Li and Muxiang Zhou
    Mol Cancer Ther May 1 2008 7 (5) 1101-1109; DOI:10.1158/1535-7163.MCT-08-0179

  • Research Articles: Therapeutics, Targets, and Development
    Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
    Shuiying Hu, Hongmei Niu, Patton Minkin, Shelley Orwick, Akira Shimada, Hiroto Inaba, Gary V.H. Dahl, Jeffrey Rubnitz and Sharyn D. Baker
    Mol Cancer Ther May 1 2008 7 (5) 1110-1120; DOI:10.1158/1535-7163.MCT-07-2218

  • Research Articles: Therapeutics, Targets, and Development
    Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
    Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Constantine Mitsiades, Arghya Ray, Rosemary Barrett, Sophia Adamia, Richard Stone, Ilene Galinsky, Andrew L. Kung and James D. Griffin
    Mol Cancer Ther May 1 2008 7 (5) 1121-1129; DOI:10.1158/1535-7163.MCT-07-2331

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells
    Ismael Samudio, Svitlana Kurinna, Peter Ruvolo, Borys Korchin, Hagop Kantarjian, Miloslav Beran, Kenneth Dunner Jr., Seiji Kondo, Michael Andreeff and Marina Konopleva
    Mol Cancer Ther May 1 2008 7 (5) 1130-1139; DOI:10.1158/1535-7163.MCT-07-0553

  • Research Articles: Therapeutics, Targets, and Development
    Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
    Anna Morena D'Alise, Giovanni Amabile, Mariangela Iovino, Francesco Paolo Di Giorgio, Marta Bartiromo, Fabio Sessa, Fabrizio Villa, Andrea Musacchio and Riccardo Cortese
    Mol Cancer Ther May 1 2008 7 (5) 1140-1149; DOI:10.1158/1535-7163.MCT-07-2051

  • Research Articles: Therapeutics, Targets, and Development
    MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer
    Tetsuya Oguri, Hiroaki Ozasa, Takehiro Uemura, Yuji Bessho, Mikinori Miyazaki, Ken Maeno, Hiroyoshi Maeda, Shigeki Sato and Ryuzo Ueda
    Mol Cancer Ther May 1 2008 7 (5) 1150-1155; DOI:10.1158/1535-7163.MCT-07-2088

  • Research Articles: Therapeutics, Targets, and Development
    Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells
    Xia Wang, Wenshu Chen, Weihua Zeng, Lang Bai, Yohannes Tesfaigzi, Steven A. Belinsky and Yong Lin
    Mol Cancer Ther May 1 2008 7 (5) 1156-1163; DOI:10.1158/1535-7163.MCT-07-2183

  • Research Articles: Therapeutics, Targets, and Development
    p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis
    Monica Schiappacassi, Francesca Lovat, Vincenzo Canzonieri, Barbara Belletti, Stefania Berton, Domenica Di Stefano, Andrea Vecchione, Alfonso Colombatti and Gustavo Baldassarre
    Mol Cancer Ther May 1 2008 7 (5) 1164-1175; DOI:10.1158/1535-7163.MCT-07-2154

  • Research Articles: Therapeutics, Targets, and Development
    LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
    Daniel B. Lipka, Linda S. Hoffmann, Florian Heidel, Boyka Markova, Marie-Christine Blum, Frank Breitenbuecher, Stefan Kasper, Thomas Kindler, Ross L. Levine, Christoph Huber and Thomas Fischer
    Mol Cancer Ther May 1 2008 7 (5) 1176-1184; DOI:10.1158/1535-7163.MCT-07-2215

  • Research Articles: Therapeutics, Targets, and Development
    SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
    Adina Vultur, Ralf Buettner, Claudia Kowolik, Wei Liang, David Smith, Frank Boschelli and Richard Jove
    Mol Cancer Ther May 1 2008 7 (5) 1185-1194; DOI:10.1158/1535-7163.MCT-08-0126

  • Research Articles: Therapeutics, Targets, and Development
    Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9
    Cheng-Wei Lin, Shing-Chun Shen, Wen-Chi Hou, Liang-Yo Yang and Yen-Chou Chen
    Mol Cancer Ther May 1 2008 7 (5) 1195-1206; DOI:10.1158/1535-7163.MCT-07-2199

  • Research Articles: Therapeutics, Targets, and Development
    Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab
    Xinqun Li, Yang Lu, Ke Liang, Tianhong Pan, John Mendelsohn and Zhen Fan
    Mol Cancer Ther May 1 2008 7 (5) 1207-1217; DOI:10.1158/1535-7163.MCT-07-2187

  • Research Articles: Therapeutics, Targets, and Development
    Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
    Randall W. Alfano, Stephen H. Leppla, Shihui Liu, Thomas H. Bugge, Meenhard Herlyn, Keiran S. Smalley, Jennifer L. Bromberg-White, Nicholas S. Duesbery and Arthur E. Frankel
    Mol Cancer Ther May 1 2008 7 (5) 1218-1226; DOI:10.1158/1535-7163.MCT-08-0024

  • Research Articles: Therapeutics, Targets, and Development
    Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis
    Shang-Chiung Chen, Dale O. Henry, Peter R. Reczek and Michael K.K. Wong
    Mol Cancer Ther May 1 2008 7 (5) 1227-1236; DOI:10.1158/1535-7163.MCT-08-0051

  • Research Articles: Therapeutics, Targets, and Development
    Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
    Gunnar Johansson, Yonatan Y. Mahller, Margaret H. Collins, Mi-Ok Kim, Takahiro Nobukuni, John Perentesis, Timothy P. Cripe, Heidi A. Lane, Sara C. Kozma, George Thomas and Nancy Ratner
    Mol Cancer Ther May 1 2008 7 (5) 1237-1245; DOI:10.1158/1535-7163.MCT-07-2335

  • Research Articles: Therapeutics, Targets, and Development
    Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
    Rui Gao, Douglas K. Price, Tristan Sissung, Eddie Reed and William D. Figg
    Mol Cancer Ther May 1 2008 7 (5) 1246-1250; DOI:10.1158/1535-7163.MCT-07-2206

  • Research Articles: Therapeutics, Targets, and Development
    The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis
    Karen Liby, Candice C. Black, Darlene B. Royce, Charlotte R. Williams, Renee Risingsong, Mark M. Yore, Xi Liu, Tadashi Honda, Gordon W. Gribble, William W. Lamph, Thomas A. Sporn, Ethan Dmitrovsky and Michael B. Sporn
    Mol Cancer Ther May 1 2008 7 (5) 1251-1257; DOI:10.1158/1535-7163.MCT-08-0023

  • Research Articles: Therapeutics, Targets, and Development
    Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice
    Komal Raina, Subapriya Rajamanickam, Gagan Deep, Meenakshi Singh, Rajesh Agarwal and Chapla Agarwal
    Mol Cancer Ther May 1 2008 7 (5) 1258-1267; DOI:10.1158/1535-7163.MCT-07-2220

  • Research Articles: Therapeutics, Targets, and Development
    Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57
    Lianjun Lu, Jianhua Qiu, Shunli Liu and Wenjing Luo
    Mol Cancer Ther May 1 2008 7 (5) 1268-1274; DOI:10.1158/1535-7163.MCT-07-2222

  • Research Articles: Therapeutics, Targets, and Development
    Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis
    Po-Lin So, Michele A. Fujimoto and Ervin H. Epstein Jr.
    Mol Cancer Ther May 1 2008 7 (5) 1275-1284; DOI:10.1158/1535-7163.MCT-07-2043

  • Research Articles: Therapeutics, Targets, and Development
    Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity
    Tatjana Mijatovic, Nancy De Nève, Philippe Gailly, Véronique Mathieu, Benjamin Haibe-Kains, Gianluca Bontempi, Javier Lapeira, Christine Decaestecker, Vincenzo Facchini and Robert Kiss
    Mol Cancer Ther May 1 2008 7 (5) 1285-1296; DOI:10.1158/1535-7163.MCT-07-2241

  • Research Articles: Therapeutics, Targets, and Development
    PBISe, a novel selenium-containing drug for the treatment of malignant melanoma
    SubbaRao V. Madhunapantula, Dhimant Desai, Arati Sharma, Sung Jin Huh, Shantu Amin and Gavin P. Robertson
    Mol Cancer Ther May 1 2008 7 (5) 1297-1308; DOI:10.1158/1535-7163.MCT-07-2267

  • Research Articles: Therapeutics, Targets, and Development
    Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
    José A. Casado, Paula Río, Esther Marco, Verónica García-Hernández, Alberto Domingo, Laura Pérez, Juan Carlos Tercero, Juan José Vaquero, Beatriz Albella, Federico Gago and Juan A. Bueren
    Mol Cancer Ther May 1 2008 7 (5) 1309-1318; DOI:10.1158/1535-7163.MCT-07-2432

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78
    Minal Kotecha, Jerome Kluza, Geoff Wells, C. Caroline O'Hare, Claudia Forni, Roberto Mantovani, Philip W. Howard, Peter Morris, David E. Thurston, John A. Hartley and Daniel Hochhauser
    Mol Cancer Ther May 1 2008 7 (5) 1319-1328; DOI:10.1158/1535-7163.MCT-07-0475

  • Research Articles: Therapeutics, Targets, and Development
    Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice
    Tao Bian, Yue Wang, Zhenhua Lu, Zhenmei Ye, Li Zhao, Jiao Ren, Hui Zhang, Li Ruan and Houwen Tian
    Mol Cancer Ther May 1 2008 7 (5) 1329-1335; DOI:10.1158/1535-7163.MCT-07-2015

Back to top
PreviousNext
Molecular Cancer Therapeutics: 7 (5)
May 2008
Volume 7, Issue 5
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data

Jump to

  • Spotlight on Clinical Response
  • Review
  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement